BK virus infection following kidney transplantation: An overview of risk factors, screening strategies, and therapeutic interventions

Current Opinion in Organ Transplantation

Volumn 19, Issue 4, 2014, Pages 401-412

  Pham, Phuong Thu ^a   Schaenman, Joanna ^b   Pham, Phuong Chi ^c  

^a Department of Medicine   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c OLIVE VIEW UCLA MEDICAL CENTER   (United States)

Author keywords

BK nephropathy; BK viremia; BK virus screening after kidney transplant; BK virus specific T cell immunity; Management of BK virus associated clinical syndromes

Indexed keywords

CIDOFOVIR; CYCLOSPORIN; IMMUNOGLOBULIN; LEFLUNOMIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; QUINOLONE DERIVATIVE; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

BK VIRUS; BK VIRUS INFECTION; CELLULAR IMMUNITY; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INTERVENTION STUDY; KIDNEY TRANSPLANTATION; REVIEW; RISK FACTOR; VIRUS REACTIVATION; VIRUS REPLICATION; ANIMAL; POLYOMAVIRUS INFECTIONS; TUMOR VIRUS INFECTIONS; VIROLOGY;

ANIMALS; BK VIRUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; POLYOMAVIRUS INFECTIONS; RISK FACTORS; TUMOR VIRUS INFECTIONS;

EID: 84904098170     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000101     Document Type: Review

References (63)

1. Gardner SD, Field AM, Coleman DV, et al. New human papovavirus (BK) isolated from the urine after renal transplantation. Lancet 1971; 1:1253-1257.
2. Pham PT, Danovitch GM, Pham PC. Medical management of the renal transplant recipient: infections and malignancies. In: Johnson, RJ, Feehally, J, (eds), Comprehensive clinical nephrology. 2014 5th edn. St. Louis, MO: Elsevier Saunders. (in press).
3. Pollara CP, Corbellini S, Chiappini S, et al. Quantitative viral load measurements for BKV infection in renal transplant recipients as a predictive tool for BKVNA. New Microbiol 2011; 34:165-171.
4. Bohl DL, Storch GA, Ryschkewitsch C, et al. Donor origin of BK virus in renal transplant and role of HLA C7 in susceptibility to sustained viremia. Am J Transplant 2005; 5:2213-2221.
5. Dadhania D, Snopkowski C, Ding R, et al. Epidemiology of BK virus in renal allograft recipients: independent risk factors for BK virus replication. Transplantation 2008; 86:521-528.
6. Sharif A, Alachkar N, Bagnasco S, et al. Incidence and outcomes of BK virus allograft among ABO- and HLA-incompatible kidney transplant recipients. Clin J Am Soc Nephrol 2012; 7:1320-1327.
7. Saundh BK, Baker R, Harris M. Early BK polyomavirus (BK) reactivation in donor kidney is a risk factor for development of BK-associated nephropathy. J Infect Dis 2013; 207:137-141.
8. Masutani K, Ninomiya T, Rhandhawa P. HLA-2 HLA-B44 and HLA-DR 15 are associated with lower risk of BK viremia. Nephrol Dial Transplant 2013; 28:3119-31126.
9. Hassig A, Roos M, Etter A, et al. Association of BK viremia with human leukocyte antigen mismatches and acute rejection, but not with type of calcineurin inhibitor. Transplant Infect Dis 2014; 16:44-54.
10. Pham PT, Uttam R. Transplantation: immunosuppression and risk of polyomavirus BK replication. Nat Rev Nephrology 2013; 9:135-136.
11. Sharma SG, Nickeleit V, Herlitz LC, et al. BK polyomavirus nephropathy in native kidneys. Nephrol Dial Transplant 2013; 28:620-631.
12. Ramos E, Drachenberg CB, Portocarrero M, et al. BK virus nephropathy diagnosis and treatment: experience at the University of Maryland Renal Transplant Program. Clin Transplant 2002; 43-53.
13. Borni-Duval C, Caillard S, Olagne S, et al. Risk factors for BK virus infection in the era of therapeutic drug monitoring. Transplantation 2013; 95:1498-1505.
14. Acott PD, O'Regan PA, Lee SH, et al. In vitro effect of cyclosporine A on primary and chronic BK polyoma virus infection in Vero E6 cells. Transpl Infect Dis 2008; 10:385-390.
15. Li YJ, Weng CH, Lai WC, et al. A suppressive effect of cyclosporine A on replication and noncoding region activation of polyomavirus BK virus. Transplantation 2010; 89:299-306.
16. Dharnidharka V, Cherikh W, Abbott KC. An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States. Transplantation 2009; 87:1019-1026.
17. Schold JD, Rehman S, Kayler LK, et al. Treatment for BK virus: incidence, risk factors and outcomes for kidney transplant recipients in the United States. Transplant Int 2009; 22:626-634.
18. Prince O, Savic S, Dickenman M, et al. Risk factors for polyomavirus nephropathy. Nephrol Dial Transplant 2009; 24:1024-1033.
19. Hirsch HH, Vincenti F, Friman S, et al. Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study. Am J Transplant 2013; 13:136-143.
20. Brennan DC, Agha I, Bohl DL, et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 2005; 5:582-594.
21. Hardinger KL, Koch MJ, Bohl DJ, et al. Polyomavirus BK (BKV) replication in renal tubular epithelial cells is inhibited by mTOR inhibitors but activated by tacrolimus in a pathway involving the FKBP12 [abstract]. Am J Transplant 2011; 497.
22. Hardinger KL, Koch MJ, Bohl DJ, et al. BK-virus and the impact of pre-emptive immunosuppression reduction: 5-year results. Am J transplant 2010; 10: 407-415.
23. Geddes CC, Gunson R, Mazonakis E, et al. BK viremia surveillance after kidney transplant: single-center experience during a change from cyclosporine to lower-dose tacrolimus-based primary immunosuppression regimen. Transplant Inf Dis 2011; 13:109-116.
24. Benavides CA, Pollard VB, Mauiyyedi S, et al. BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes. Transplantation 2007; 84:83-88.
25. Tedesco Silva H Jr, Cibrik D, Johnston T, et al. Everolimus plus reducedexposure CSA versus mycophenolic acid plus standard exposure CSA in renal-transplant recipients. Am J Transplant 2010; 10:1401-1413.
26. Araki K, Turner AP, Shaffer VO, et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009; 460:108-112.
27. Liacini A, Seamone ME, Murvue DA, et al. Anti-BK virus mechanisms of sirolimus and leflunomide alone or in combination: toward a new therapy for BK virus infection. Transplantation 2010; 90:1450-1457.
28. Lipshutz GS, Flechner SM, Govani MV, et al. BK nephropathy in kidney transplant recipients treated with calcineurin inhibitor-free immunosuppression regimen. Am J Transplant 2004; 4:2132-2134.
29. Hymes LC, Warshaw BL. Five-year experience using sirolimus-base calcineurin inhibitor-free immunosuppression in pediatric renal transplantation. Pediatr Transplant 2011; 15:437-441.
30. Cosio FG, Amer H, Grande JP, et al. Comparison of low-versus high tacrolimus levels in kidney transplantation: assessment of efficacy by protocol biopsies. Transplantation 2007; 83:411-416.
31. Mengel M, Marwedel M, Radermacher J, et al. Incidence of polyomavirusnephropathy in renal allografts: influence of modern immunosuppressive drugs. Nephrol Dial Transplant 2003; 18:1190-1196.
32. Hirsch HH, Mohaupt M, Klimkait T. Prospective monitoring of BK virus load after discontinuing sirolimus treatment in a renal transplant patient with BK virus nephropathy [letter to the editor]. J Inf Dis 2001; 184:1494-1495.
33. Sood P, Senanayake S, Sujeet K, et al. Management and outcome of BK viremia in renal transplant recipients: a prospective single-center study. Transplantation 2012; 94:814-821.
34. Schaub S, Hirsch HH, Dickenmann M, et al. Reducing immunosuppression preserves allograft function in presumptive and definitive polyomavirus- associated nephropathy. Am J transplant 2010; 10:2615-2623.
35. Elfadawy N, Flechner SM, Liu X, et al. The impact of surveillance and rapid reduction in immunosuppression to control BK virus-related graft injury in kidney transplantation. Transplantation 2013; 26:822-832.
36. Schwarz A, Linnenweber-Held S, Heim A, et al. Factors influencing viral clearing and renal function during BK-associated nephropathy after renal transplant. Transplantation 2012; 94:396-402.
37. Hirsch HH, Randhawa P; AST infectious Diseases Community of Practice. BK polyomavirus in solid organ transplantation. Am J Transplant 2013; 13:179- 188.
38. Williams J, Javaid B, Kadambi PV. Leflunomide for polyomavirus type BK nephropathy. N Engl J Med 2005; 325:1157-1158.
39. Zaman RA, Ettenger RB, Cheam H, et al. A novel treatment regimen for BK viremia. Transplantation 2014. [Epub ahead of print]
40. Josephson MA, Williams JW, Chandraker A, et al. Polyomavirus-associated nephropathy: update on antiviral strategies. Transplant Inf Dis 2012; 8:95-101.
41. Krisi JC, Taber DJ, Pilch N, et al. Leflunomide efficacy and pharmacokinetics for the treatment of BK viral infection. Clin J Am Soc Nephrol 2012; 7:1003-1009.
42. Josephson MA, Gillen D, Javaid B, et al. Treatment of renal allograft polyoma BK virus infection with leflunomide. Transplantation 2006; 15:704-710.
43. Faguer S, Hirsch HH, Kamar N, et al. Leflunomide treatment for polyomavirus BK-associated nephropathy after kidney transplantation. Transplant Int 2007; 20:962-969.
44. Johnston O, Jaswal D, Gill JS, et al. Treatment of polyomavirus infection in kidney transplant recipients: a systematic review. Transplantation 2010; 89:1057-1070.
45. Guasch A, Roy-Chaudhury P, Woodle ES, et al. Assessment of efficacy and safety of FK778 in comparison with standard care in renal transplant recipients with untreated BK nephropathy. Transplantation 2010; 90:891-897.
46. Kuypers DR, Vandooren AK, Lerut E, et al. Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients. Am J Transplant 2005; 5:1997-2004.
47. Kuypers DRJ, Bammens B, Claes K, et al. A single-center study of adjuvant cidofovir therapy for BK virus interstitial nephritis (BKVIN) in renal allograft recipients. J Antimicrobial Chemotherapy 2009; 63:417-419.
48. Wu SW, Chang HR, Lian JD. The effect of low-dose cidofovir on the long-term outcome of polyomavirus-associated nephropathy in renal transplant recipients. Nephrol Dial Transplant 2009; 24:1034-1038.
49. Gabardi S, Waikan SS, Martin S, et al. Evaluation of fluoroquinolones for the prevention of BK viremia after renal transplantation. Clin J Am Soc Nephrol 2010; 5:1298-1304.
50. Wojciechowski D, Chanda R, Chandran S, et al. Ciprofloxacin prophylaxis in kidney transplant recipients reduces BK virus infection at 3 months but not at 1 year. Transplantation 2012; 94:1117-1123.
51. Lee BT, Gabardi S, Grafals M, et al. Efficacy of levofloxacin in the treatment of BK viremia: a multicenter, double-blinded, randomized, placebo-controlled trial. Clin J Am Soc Nephrol 2014; 9:583-589.
52. Randhawa PS, Schonder K, Shapiro R, et al. Polyomavirus BK neutralizing activity in human immunoglobulin preparations. Transplantation 2010; 89:1462-1465.
53. Bohl DL, Brennan DC, Ryschkewitsch C, et al. BK virus antibody titers and intensity of infections after renal transplantation. J Clin Virol 2008; 43:184-189.
54. Chen Y, Trofe J, Gordon J, et al. Interplay of cellular and humoral immune responses against BK virus in kidney transplant recipients with polyomavirus nephropathy. J Virol 2006; 80:3495-3505.
55. Renner FC, Dietrich H, Bulut N, et al. The risk of polyomavirus- associated graft nephropathy is increased by a combined suppression of CD8 and CD4 celldependent immune effects. Transplant Proc 2013; 45:1608-1610.
56. Trydzenskaya H, Sattler A, Muller K, et al. Novel approach for improved assessment of phenotypic and functional characteristics of BKV-specific T-cell immunity. Transplantation 2011; 92:1269-1277.
57. Elfadawy N, Flechner SM, Schold JD, et al. Transient versus persistent BK viremia and long-term outcomes after kidney and kidney-pancreas transplantation. Clin J Amer Soc Nephrol 2014; 9:1-10.
58. Scharwz A, Linnenweber-Held S, Heim A, Brocker V, et al. Factors influencing viral clearing and renal function during polyomavirus BK-associated nephropathy after renal transplantation. Transplantation 2012; 94:396-402.
59. Kasiske BL, Zeier MG, Chapman JR, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int 2010; 77:299-311.
60. Casadei DH, Del CRM, Opelz G, et al. A randomized and prospective study comparing treatment with high dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation 2011; 71:53-58.
61. Luke PP, Scantlebury VP, Jordan ML, et al. Reversal of steroid- and antilymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients. Transplantation 2001; 72:419-422.
62. Mommeja Marin H, Marty F, Boeckh. M et al. CMX001 may mitigate signs of BK virus (BKV) associated bladder and kidney end-organ damage; 24th International Congress of The Transplantation Society; 15-17 July 2012; Berlin. Germany.
63. Pastrana DV, Brennan DC, Cuburu N, et al. Neutralization serotyping of BK polyomavirus infection in kidney transplant recipients. PLoS Pathol 2012; 8:e1002650.